Citigroup
OLMA icon

Citigroup’s Olema Pharmaceuticals OLMA Stock Holding History

Citigroup’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$411K Sell
27,578
-119,785
-81% -$2.67M ﹤0.01% 3658
2025
Q4 		$3.68M Buy
147,363
+126,917
+621% +$2.26M ﹤0.01% 2231
2025
Q3 		$200K Sell
20,446
-49,885
-71% -$300K ﹤0.01% 3995
2025
Q2 		$300K Buy
70,331
+39,340
+127% +$175K ﹤0.01% 3876
2025
Q1 		$117K Sell
30,991
-37,005
-54% -$186K ﹤0.01% 4511
2024
Q4 		$396K Buy
67,996
+37,899
+126% +$379K ﹤0.01% 3993
2024
Q3 		$359K Buy
30,097
+6,345
+27% +$81.1K ﹤0.01% 3944
2024
Q2 		$257K Sell
23,752
-226,230
-90% -$2.45M ﹤0.01% 3762
2024
Q1 		$2.83M Buy
249,982
+245,175
+5,100% +$3.16M ﹤0.01% 2140
2023
Q4 		$67.4K Buy
4,807
+4,792
+31,947% +$64.4K ﹤0.01% 4384
2023
Q3 		$186 Sell
15
-7,979
-100% -$81.3K ﹤0.01% 5329
2023
Q2 		$72.2K Sell
7,994
-1,918
-19% -$11.6K ﹤0.01% 4413
2023
Q1 		$34.4K Buy
+9,912
New +$40.4K ﹤0.01% 4362
2022
Q4 		– Sell
-1,196
Closed -$3K – 5904
2022
Q3 		$3K Sell
1,196
-466
-28% -$1.98K ﹤0.01% 5401
2022
Q2 		$7K Sell
1,662
-6,317
-79% -$20K ﹤0.01% 5506
2022
Q1 		$34K Sell
7,979
-289
-3% -$1.59K ﹤0.01% 4901
2021
Q4 		$77K Buy
8,268
+5,253
+174% +$109K ﹤0.01% 4862
2021
Q3 		$83K Buy
3,015
+297
+11% +$8.02K ﹤0.01% 4483
2021
Q2 		$76K Buy
2,718
+1,531
+129% +$43.6K ﹤0.01% 4627
2021
Q1 		$39K Sell
1,187
-5,725
-83% -$245K ﹤0.01% 4842
2020
Q4 		$332K Buy
+6,912
New +$324K ﹤0.01% 4577

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citigroup's OLMA Position: Q1 2026 in Review

Citigroup reduced its Olema Pharmaceuticals (OLMA) stake by 81% in Q1 2026, selling an estimated $2.67M and leaving 27,578 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

Citigroup first reported a position in OLMA in Q4 2020 and has held it in 21 quarters since. The position peaked at $3.68M in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Citigroup held 27,578 shares of Olema Pharmaceuticals worth $411K as of Q1 2026.
  • Citigroup sold 119,785 Olema Pharmaceuticals shares in Q1 2026, an estimated $2.67M.
  • Olema Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3658 holding.
  • Citigroup first reported a position in Olema Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Citigroup's Olema Pharmaceuticals position peaked at $3.68M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.